Accessibility Menu
 
Dianthus Therapeutics logo

Dianthus Therapeutics

(NASDAQ) DNTH

Current Price$84.70
Market Cap$4.44B
Since IPO (2023)+663%
5 Year-59%
1 Year+363%
1 Month+52%

Dianthus Therapeutics Financials at a Glance

Market Cap

$4.44B

Revenue (TTM)

$2.04M

Net Income (TTM)

$0.00

EPS (TTM)

$-4.11

P/E Ratio

-20.40

Dividend

$0.00

Beta (Volatility)

0.99 (Low)

Price

$84.70

Volume

39,064

Open

$85.00

Previous Close

$84.70

Daily Range

$83.89 - $88.33

52-Week Range

$13.37 - $88.49

DNTH: Motley Fool Moneyball Superscore

64

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Dianthus Therapeutics

Industry

Biotechnology

Employees

92

CEO

Marino Garcia, MBA

Headquarters

New York City, NY 10036, US

DNTH Financials

Key Financial Metrics (TTM)

Gross Margin

100%

Operating Margin

-87%

Net Income Margin

0%

Return on Equity

-38%

Return on Capital

-36%

Return on Assets

0%

Earnings Yield

-4.90%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.44B

Shares Outstanding

52.94M

Volume

39.06K

Short Interest

0.00%

Avg. Volume

1.08M

Financials (TTM)

Gross Profit

$2.04M

Operating Income

$177.93M

EBITDA

$177.93M

Operating Cash Flow

$129.06M

Capital Expenditure

$213.00K

Free Cash Flow

$129.27M

Cash & ST Invst.

$404.30M

Total Debt

$1.39M

Dianthus Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$284.00K

-78.6%

Gross Profit

$284.00K

-78.6%

Gross Margin

100.00%

N/A

Market Cap

$4.44B

N/A

Market Cap/Employee

$56.96M

N/A

Employees

78

N/A

Net Income

$97.91M

+444.3%

EBITDA

$69.28M

-117.6%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$402.91M

+47.2%

Accounts Receivable

$102.00K

-87.4%

Inventory

$0.00

N/A

Long Term Debt

$1.02M

-13.0%

Short Term Debt

$367.00K

+14.7%

Return on Assets

0.00%

N/A

Return on Invested Capital

-35.57%

N/A

Free Cash Flow

$47.12M

-71.5%

Operating Cash Flow

$46.98M

-71.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ELVNEnliven Therapeutics, Inc.
$37.79-3.60%
ANABAnaptysBio, Inc.
$56.73+2.29%
OCSOculis Holding AG
$27.03+1.65%
NKTRNektar Therapeutics
$75.71+5.23%

Trending Stocks

Symbol / CompanyPricePrice Chg
CYCNCyclerion Therapeutics
$6.38+3.12%
INTCIntel
$48.03+0.09%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.23+0.04%
NKENike
$44.63-0.16%

Questions About DNTH

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.